Trump Media adviser Katie Zacharia was named White House press secretary and criticized over past posts. The story reports no change to Trump Media’s business.
The criticism could draw attention to Zacharia’s past work at Trump Media. But the story reports no change to the company’s products, sales, or operations, so it does not change the company’s outlook.
The story mentions Moderna’s recent share rise but reports no new company development or link between the dispute and Moderna’s business.
The story mentions Vaxcyte’s recent share rise but reports no new company development or link between the dispute and Vaxcyte’s business.
The story mentions Novavax’s recent share rise but reports no new company development or link between the dispute and Novavax’s business.
The story mentions Eli Lilly’s recent share rise but reports no new company development or link between the dispute and Eli Lilly’s business.
The story mentions Merck’s recent share decline but reports no new company development or link between the dispute and Merck’s business.
Follow Trump Media & Technology (DJT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for DJT